Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Primary Biliary Cirrhosis Drug market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Primary Biliary Cirrhosis Drugmarket, defines the market attractiveness level of Primary Biliary Cirrhosis Drug market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Primary Biliary Cirrhosis Drug industry, describes the types of Primary Biliary Cirrhosis Drug market, the applications of major players and the market size, and deeply analyzes the current situation of the global Primary Biliary Cirrhosis Drug market and the development prospects and opportunities of Primary Biliary Cirrhosis Drug industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Primary Biliary Cirrhosis Drug market in Chapter 13.
By Player:
GlaxoSmithKline Plc
Enanta Pharmaceuticals, Inc
AlbireoPharma
Dr Falk Pharma GmbH
Johnson & Johnson
CymaBay Therapeutics, Inc
Virobay Inc
MediGene AG
Intercept Pharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
By Type:
Budesonide
FFP-104
GSK-2330672
MBX-8025
NGM-282
Others
By End-User:
Clinic
Hospital
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Primary Biliary Cirrhosis Drug Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Primary Biliary Cirrhosis Drug Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Primary Biliary Cirrhosis Drug Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Primary Biliary Cirrhosis Drug Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Primary Biliary Cirrhosis Drug Market Analysis and Outlook to 2022
-
7.1 Global Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
7.2 United States Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
7.3 Europe Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
7.4 China Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
7.5 Japan Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
7.6 India Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
7.7 South Korea Primary Biliary Cirrhosis Drug Consumption (2017-2022)
8 Region and Country-wise Primary Biliary Cirrhosis Drug Market Analysis and Outlook to 2028
-
8.1 Global Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
8.2 United States Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
8.3 Europe Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
8.4 China Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
8.5 Japan Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
8.6 India Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
8.7 South Korea Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
9 Global Primary Biliary Cirrhosis Drug Market Outlook by Types and Applications to 2022
-
9.1 Global Primary Biliary Cirrhosis Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Budesonide Consumption and Growth Rate (2017-2022)
-
9.1.2 Global FFP-104 Consumption and Growth Rate (2017-2022)
-
9.1.3 Global GSK-2330672 Consumption and Growth Rate (2017-2022)
-
9.1.4 Global MBX-8025 Consumption and Growth Rate (2017-2022)
-
9.1.5 Global NGM-282 Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Primary Biliary Cirrhosis Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Global Primary Biliary Cirrhosis Drug Market Outlook by Types and Applications to 2028
-
10.1 Global Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Budesonide Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global FFP-104 Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global GSK-2330672 Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global MBX-8025 Consumption Forecast and Growth Rate (2022-2028)
-
10.1.5 Global NGM-282 Consumption Forecast and Growth Rate (2022-2028)
-
10.1.6 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global Primary Biliary Cirrhosis Drug Import and Export Analysis (Top 5 Countries)
-
11.1 Global Primary Biliary Cirrhosis Drug Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Primary Biliary Cirrhosis Drug Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Primary Biliary Cirrhosis Drug Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Primary Biliary Cirrhosis Drug Market Competitive Analysis
-
14.1 GlaxoSmithKline Plc
-
14.1.1 GlaxoSmithKline Plc Company Details
-
14.1.2 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product and Service
-
14.2 Enanta Pharmaceuticals, Inc
-
14.2.1 Enanta Pharmaceuticals, Inc Company Details
-
14.2.2 Enanta Pharmaceuticals, Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Enanta Pharmaceuticals, Inc Primary Biliary Cirrhosis Drug Product and Service
-
14.3 AlbireoPharma
-
14.3.1 AlbireoPharma Company Details
-
14.3.2 AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 AlbireoPharma Primary Biliary Cirrhosis Drug Product and Service
-
14.4 Dr Falk Pharma GmbH
-
14.4.1 Dr Falk Pharma GmbH Company Details
-
14.4.2 Dr Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Dr Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product and Service
-
14.5 Johnson & Johnson
-
14.5.1 Johnson & Johnson Company Details
-
14.5.2 Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Product and Service
-
14.6 CymaBay Therapeutics, Inc
-
14.6.1 CymaBay Therapeutics, Inc Company Details
-
14.6.2 CymaBay Therapeutics, Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 CymaBay Therapeutics, Inc Primary Biliary Cirrhosis Drug Product and Service
-
14.7 Virobay Inc
-
14.7.1 Virobay Inc Company Details
-
14.7.2 Virobay Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Virobay Inc Primary Biliary Cirrhosis Drug Product and Service
-
14.8 MediGene AG
-
14.8.1 MediGene AG Company Details
-
14.8.2 MediGene AG Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 MediGene AG Primary Biliary Cirrhosis Drug Product and Service
-
14.9 Intercept Pharmaceuticals, Inc
-
14.9.1 Intercept Pharmaceuticals, Inc Company Details
-
14.9.2 Intercept Pharmaceuticals, Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Intercept Pharmaceuticals, Inc Primary Biliary Cirrhosis Drug Product and Service
-
14.10 NGM Biopharmaceuticals, Inc
-
14.10.1 NGM Biopharmaceuticals, Inc Company Details
-
14.10.2 NGM Biopharmaceuticals, Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 NGM Biopharmaceuticals, Inc Primary Biliary Cirrhosis Drug Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Primary Biliary Cirrhosis Drug
-
Figure Primary Biliary Cirrhosis Drug Picture
-
Table Global Primary Biliary Cirrhosis Drug Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Primary Biliary Cirrhosis Drug Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Primary Biliary Cirrhosis Drug Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Primary Biliary Cirrhosis Drug Consumption by Country (2017-2022)
-
Figure United States Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Table Europe Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure China Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure India Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Global Primary Biliary Cirrhosis Drug Consumption Forecast by Country (2022-2028)
-
Figure United States Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Budesonide Consumption and Growth Rate (2017-2022)
-
Figure Global FFP-104 Consumption and Growth Rate (2017-2022)
-
Figure Global GSK-2330672 Consumption and Growth Rate (2017-2022)
-
Figure Global MBX-8025 Consumption and Growth Rate (2017-2022)
-
Figure Global NGM-282 Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Budesonide Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global FFP-104 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global GSK-2330672 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global MBX-8025 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global NGM-282 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Primary Biliary Cirrhosis Drug Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Primary Biliary Cirrhosis Drug Export by Region (Top 5 Countries) (2017-2028)
-
Table GlaxoSmithKline Plc (Foundation Year, Company Profile and etc.)
-
Table GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product and Service
-
Table Enanta Pharmaceuticals, Inc (Foundation Year, Company Profile and etc.)
-
Table Enanta Pharmaceuticals, Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Enanta Pharmaceuticals, Inc Primary Biliary Cirrhosis Drug Product and Service
-
Table AlbireoPharma (Foundation Year, Company Profile and etc.)
-
Table AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table AlbireoPharma Primary Biliary Cirrhosis Drug Product and Service
-
Table Dr Falk Pharma GmbH (Foundation Year, Company Profile and etc.)
-
Table Dr Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Dr Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product and Service
-
Table Johnson & Johnson (Foundation Year, Company Profile and etc.)
-
Table Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Johnson & Johnson Primary Biliary Cirrhosis Drug Product and Service
-
Table CymaBay Therapeutics, Inc (Foundation Year, Company Profile and etc.)
-
Table CymaBay Therapeutics, Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table CymaBay Therapeutics, Inc Primary Biliary Cirrhosis Drug Product and Service
-
Table Virobay Inc (Foundation Year, Company Profile and etc.)
-
Table Virobay Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Virobay Inc Primary Biliary Cirrhosis Drug Product and Service
-
Table MediGene AG (Foundation Year, Company Profile and etc.)
-
Table MediGene AG Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table MediGene AG Primary Biliary Cirrhosis Drug Product and Service
-
Table Intercept Pharmaceuticals, Inc (Foundation Year, Company Profile and etc.)
-
Table Intercept Pharmaceuticals, Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Intercept Pharmaceuticals, Inc Primary Biliary Cirrhosis Drug Product and Service
-
Table NGM Biopharmaceuticals, Inc (Foundation Year, Company Profile and etc.)
-
Table NGM Biopharmaceuticals, Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table NGM Biopharmaceuticals, Inc Primary Biliary Cirrhosis Drug Product and Service
-
